Related Experiment Videos
[Changes in lymphocyte subsets s and treatment with beta interferon in active multiple sclerosis]
J M Gata1, J M García-Moreno, L Dinca
1Servicio de Neurología, Hospital Universitario Virgen de la Macarena, Sevilla, España.
Revista De Neurologia
|February 10, 1999
Summary
Interferon beta treatment in Multiple Sclerosis (MS) patients significantly decreases CD8 T cells and elevates the CD4/CD8 T cell ratio. These changes indicate a potential immunomodulatory effect of interferon beta in MS.
Area of Science:
- Immunology
- Neuroscience
- Pharmacology
Background:
- Multiple Sclerosis (MS) is an autoimmune disease affecting the central nervous system.
- Interferon beta (IFN beta) is a common therapeutic agent for MS.
- The immunomodulatory effects of IFN beta, particularly on T cell populations, require further elucidation.
Purpose of the Study:
- To investigate the in vivo effects of interferon beta on CD8 T cell percentage and the CD4/CD8 T cell ratio in patients with Multiple Sclerosis.
- To compare the efficacy of natural (nIFN) and recombinant (rIFN) beta interferon in modulating T cell subsets.
Main Methods:
- A cohort of 40 patients with active, clinically definite MS were studied.
- Patients received either nIFN or rIFN beta therapy.
- T cell subpopulations (CD3, CD4, CD8, NK) were analyzed using flow cytometry at regular intervals.
Main Results:
- Interferon beta treatment led to a statistically significant decrease in CD8 T cell percentage in both nIFN and rIFN groups.
- The CD4/CD8 T cell ratio showed a significant increase above the cut-off value in both treatment groups.
- The increase in the CD4/CD8 T cell ratio was observed earlier in the rIFN-treated group.
Conclusions:
- Both nIFN and rIFN beta effectively decrease CD8 T cell percentage in MS patients.
- Interferon beta therapy increases the CD4/CD8 T cell ratio in vivo.
- Recombinant IFN beta may induce these immunomodulatory changes more rapidly than natural IFN beta.